All In Biotech

Drug Trial Radar · NCT02149108

Nintedanib (BIBF 1120) vs Placebo in Refractory Metastatic Colorectal Cancer (LUME-Colon 1)

A Double-blind, Randomised, Placebo Controlled Phase III Study of Nintedanib Plus Best Supportive Care (BSC) Versus Placebo Plus BSC in Patients With Metastatic Colorectal Cancer Refractory to Standard Therapies.

Last checked: Nov 20, 2026Latest source record: Jul 21, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 768 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

768

Actual

Start

Sep 25, 2014

Primary completion

May 13, 2016

Study completion Aug 25, 2016

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
May 29, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of this Phase III study is to evaluate the efficacy of nintedanib in patients with metastatic colorectal cancer (mCRC) after failure of previous treatment with standard chemotherapy and biological agents.

Conditions

  • Colorectal Neoplasms

Interventions

  • Nintedanib (BIBF 1120)Drug

  • PlaceboDrug

  • BSCDrug

  • BSCDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS) by Central Review AssessmentTime frame: From randomisation until cut-off date 14JUN2016.
  2. Overall Survival (OS)Time frame: From randomisation until cut-off date 14JUN2016.

Locations

129 sites in 25 countries. Site status is shown where the registry gives one.

  • 1199.52.0108 Boehringer Ingelheim Investigational Site

    Los Angeles, California

  • 1199.52.0105 Boehringer Ingelheim Investigational Site

    New Haven, Connecticut

  • 1199.52.0101 Boehringer Ingelheim Investigational Site

    Plainville, Connecticut

  • 1199.52.0121 Boehringer Ingelheim Investigational Site

    Arlington Heights, Illinois

  • 1199.52.0123 Boehringer Ingelheim Investigational Site

    Sioux City, Iowa

  • 1199.52.0104 Boehringer Ingelheim Investigational Site

    Topeka, Kansas

  • 1199.52.0114 Boehringer Ingelheim Investigational Site

    New Orleans, Louisiana

  • 1199.52.0113 Boehringer Ingelheim Investigational Site

    Detroit, Michigan

  • 1199.52.0125 Boehringer Ingelheim Investigational Site

    Omaha, Nebraska

  • 1199.52.0119 Boehringer Ingelheim Investigational Site

    Johnson City, New York

  • 1199.52.0115 Boehringer Ingelheim Investigational Site

    Canton, Ohio

  • 1199.52.0106 Boehringer Ingelheim Investigational Site

    Sylvania, Ohio

  • 1199.52.0102 Boehringer Ingelheim Investigational Site

    Nashville, Tennessee

  • 1199.52.0120 Boehringer Ingelheim Investigational Site

    Fort Worth, Texas

  • 1199.52.5404 Boehringer Ingelheim Investigational Site

    Cdad. de Córdoba, Argentina

  • 1199.52.5405 Boehringer Ingelheim Investigational Site

    Cdad. de Córdoba, Argentina

  • 1199.52.5401 Boehringer Ingelheim Investigational Site

    Ciudad Autónoma de Bs As, Argentina

  • 1199.52.5403 Boehringer Ingelheim Investigational Site

    Ciudad Autónoma de Bs As, Argentina

  • 1199.52.5406 Boehringer Ingelheim Investigational Site

    Ciudad Autónoma de Bs As, Argentina

  • 1199.52.6102 Boehringer Ingelheim Investigational Site

    Concord, New South Wales, Australia

  • 1199.52.6103 Boehringer Ingelheim Investigational Site

    St Leonards, New South Wales, Australia

  • 1199.52.6101 Boehringer Ingelheim Investigational Site

    Wollongong, New South Wales, Australia

  • 1199.52.6104 Boehringer Ingelheim Investigational Site

    Heidelberg, Victoria, Australia

  • 1199.52.6105 Boehringer Ingelheim Investigational Site

    Nedlands, Western Australia, Australia

  • 1199.52.6106 Boehringer Ingelheim Investigational Site

    Perth, Western Australia, Australia

  • 1199.52.4302 Boehringer Ingelheim Investigational Site

    Linz, Austria

  • 1199.52.4303 Boehringer Ingelheim Investigational Site

    Vienna, Austria

  • 1199.52.4304 Boehringer Ingelheim Investigational Site

    Vienna, Austria

  • 1199.52.3208 Boehringer Ingelheim Investigational Site

    Aalst, Belgium

  • 1199.52.3205 Boehringer Ingelheim Investigational Site

    Bonheiden, Belgium

  • 1199.52.3202 Boehringer Ingelheim Investigational Site

    Brussels, Belgium

  • 1199.52.3207 Boehringer Ingelheim Investigational Site

    Charleroi, Belgium

  • 1199.52.3204 Boehringer Ingelheim Investigational Site

    Edegem, Belgium

  • 1199.52.3203 Boehringer Ingelheim Investigational Site

    Haine-Saint-Paul, Belgium

  • 1199.52.3201 Boehringer Ingelheim Investigational Site

    Leuven, Belgium

  • 1199.52.3206 Boehringer Ingelheim Investigational Site

    Liège, Belgium

  • 1199.52.3521 Boehringer Ingelheim Investigational Site

    Luxembourg, Belgium

  • 1199.52.1003 Boehringer Ingelheim Investigational Site

    Vancouver, British Columbia, Canada

  • 1199.52.1004 Boehringer Ingelheim Investigational Site

    Edmonton, Ontario, Canada

  • 1199.52.1001 Boehringer Ingelheim Investigational Site

    Toronto, Ontario, Canada

Showing 40 of 129 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.